Idebenone (noben) - from theory to practice

Rachin A.P.; Averchenkova A.A.

doi:https://doi.org/

Rachin A.P.

Kafedra nevrologii i psikhiatrii fakulteta povysheniia kvalifikatsii Smolenskoĭ gosudarstvennoĭ meditsinskoĭ akademii

ORCID: 0000-0003-4266-0050

Averchenkova A.A.

Idebenone (noben) - from theory to practice

Authors:

Rachin A.P., Averchenkova A.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(5): 81‑84

Read: 47463 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Rachin AP, Averchenkova AA. Idebenone (noben) - from theory to practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(5):81‑84. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

References:

Voronkova K.V., Meleshkov M.N. Noben (idebenon) v lechenii dementsii i narushenii pamyati bez dementsii. Zhurn nevrol i psikhiat 2008; 108: 4: 27-32.
Damulin I.V. Primenenie idebenona (nobena) v nevrologicheskoi praktike. Zhurn nevrol i psikhiat 2006; 106: 66-71.
Illarioshkin S.N., Ershova M.V. Primenenie idebenona dlya korrektsii mitokhondrial'noi patologii pri bolezni Fridreikha. Consilium medicum 2007; 8: 107-107.
Kotov S.V., Sidorova O.P. Noben (idebenon) v lechenii khorei Gentingtona. Shestaya Mezhregional'naya nauchno prakticheskaya konferentsiya, posvyashchennaya smezhnym voprosam nevrologii i psikhiatrii. Novosibirsk, Tomsk 27-28 maya 2009 goda.
Barkworth M., Dyde S., Johnson K. et al. An early phase I study to determine the tolerance, safety and pharmacokinetics of idebenone following multiple oral doses. Arzneimittelforschung 1985; 35: 1704-1707.
Bergamasco B., Scarzella L., La Commare P. Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type. Funct Neurol 1994; 9: 3: 161-168.
Bodmer M., Vankan P., Dreier M. et al. Pharmacokinetics and metabolism of idebenone in healthy male subjects. Eur J Clin Pharmacol. 19 November 2008.
Boni J., Maugeri A., Zingali G. et al. Steady-state pharmacokinetics of idebenone in healthy volunteers. Archives of gerontology and geriatrics 1992; 15: 3: 197-205.
Cooper J. et al. Coenzyme Q10 and vitamin E deficiency in Friedreichs ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol 2008; 15: 12: 1371-1379.
Di Prospero N., Sumner Ch., Penzak S. et al. Safety, Tolerability, and Pharmacokinetics of High-Dose Idebenone in Patients With Friedreich Ataxia. Arch Neurol 2007; 64: 803-808.
Di Prospero N.A., Baker A., Jeffries N., Fischbeck K.H. Neurological effects of high-dose idebenone in patients with Friedreichs ataxia: a randomised, placebo-controlled trial. Lancet Neurol 2007; 6: 10: 878-886.
Ferrante K. et al. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 2005; 65: 11: 1834-1836.
Gutzmann H., Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimers disease: update on a 2-year double-blind multicentre study. J Neurol Transm Suppl 1998; 54: 301-310.
Gutzmann H., Kiihl K.P., Hadler D., Rapp M.A. Safety and efficacy of idebenone versus tacrine in patients with Alzheimers disease: results of a randomized, double-blind, parallel-group multicenter study. Pharmacopsychiatry 2002; 35: l: 12-18.
Hart P.E. et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol 2005; 62: 4: 621-626.
Horstink M., van Engelen B. The effect of coenzyme Q10 therapy in Parkinson disease could be symptomatic. Arch Neurol 2003; 60: 8: 1170
HSG Cambridge, MA: HDF Biennial Symposia; 2005. PRE2CARE: A dosage ranging trial of coenzyme Q10 in Huntingtons disease and normal subjects [abstract].
Kakihana M., Yamazaki N., Nagaoka A. Effects of idebenone on the levels acetylcholine, choline, free fatty acids, and energy metabolites in the brain of rats with cerebral ischemia. Arch Gerontol Geriat 1989; 8: 247-256.
Kaufmann P. et al. Phase II trial of CoQIO for ALS finds insufficient evidence to justify phase III. Ann Neurol 2009; 66: 2: 235-244.
Koroshetz W. et al. Energy metabolism defects in Huntingtons disease and effects of coenzyme Q10. Ann Neurol 1997; 41: 2: 160-165.
Kutz K., Drewe J., Vankan P. Pharmacokinetic properties and metabolism of idebenone. J Neurol 2009; 256: 31-35.
Mar Trujillo-Martin M., Pedro Serrano-Aguilar et al. Effectiveness and safety of treatments for degenerative ataxias: A systematic review. Movement Disorders 24: 8: 1111-1124.
Marigliano V., Abate G., Barbagallo-Sangiorgi G. et al. Randomized, double-blind, placebo controlled, multicentre study of idebenone in patients suffering from multi-infarct dementia. Arch Gerontol Geriat 1992; 15: 3: 239-248.
Meier T., Buyse G. Idebenone: an emerging therapy for Fridreich ataxia. S Neurol 2009; Suppl. l: 25-30.
Myers L., Farmer J.M., Wilson R.B. et al. Antioxidant use in Friedreich ataxia. J Neurol Sci 2008; 267: 1-2: 174-176.
Muller T. et al. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinsons disease. Neurosci Lett 2003; 341: 3: 201-204.
Pisano P., Durand A., Autret E. et al. Plasma concentrations and pharmacokinetics of idebenone and its metabolites following single and repeated doses in young patients with mitochondrial encephalomyopathy. Eur J Clin Pharmacol 1996; 51: 167-169.
Ribai P., Pousset F., Tanguy M.L. et al. Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up. Arch Neurol 2007; 64: 4: 558-564.
Shults S. et al. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology 1998; 50: 3: 793-795.
Shults C. et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002; 59: 10: 1541-1550.
Stamelou M. et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord 2008; 15: 942-949.
Sugiyama Y., Fujita T. Stimulation of respiratory and phosphorylating activities in rat brain mitochondria by idebenone (CV-2619), a new agent improving cerebral metabolism. FEBS Lett 1985; 184: 48-51.
Suno M., Terashita Z., Nagaoka A. Ingibition of platelet aggregation by idebenone and mechanism of the ingibition. Arch Gerontol Geriat 1989; 8: 313-321.
Weyer G., Babej-Dolle R., Hadler D. et al. A controlled study of 2 doses of idebenone in the treatment of Alzheimers disease. Neuropsychobiology 1997; 36: 2: 73-82.